These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21503406)

  • 61. High resistance to fourth-generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases isolated in Portugal.
    Fernandes R; Gestoso A; Freitas JM; Santos P; Prudêncio C
    Int J Antimicrob Agents; 2009 Feb; 33(2):184-5. PubMed ID: 18926667
    [No Abstract]   [Full Text] [Related]  

  • 62. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany.
    Lübbert C; Straube L; Stein C; Makarewicz O; Schubert S; Mössner J; Pletz MW; Rodloff AC
    Int J Med Microbiol; 2015 Jan; 305(1):148-56. PubMed ID: 25547265
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetic environment of β-lactamase genes of extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates from patients with lower respiratory tract infection in China.
    Liu L; Wang X; An S; Zhang X; Chen L; Li Y; Xu L; Zhang Y; Gao Z
    Chin Med J (Engl); 2014; 127(13):2445-50. PubMed ID: 24985581
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America--2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Villegas MV; Blanco MG; Sifuentes-Osornio J; Rossi F
    Braz J Infect Dis; 2011; 15(1):34-9. PubMed ID: 21412587
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative evaluation of six phenotypic methods for detecting extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Singh RM; Singh HL
    J Infect Dev Ctries; 2014 Apr; 8(4):408-15. PubMed ID: 24727505
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.
    Avery LM; Mullane EM; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105863. PubMed ID: 31870597
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter isolates.
    Towne TG; Lewis JS; Herrera M; Wickes B; Jorgensen JH
    J Clin Microbiol; 2010 Jan; 48(1):298-9. PubMed ID: 19923476
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [In vitro activity of cefepime against ESBL-positive clinical strains of gram-negative rods].
    Rokosz A; Sawicka-Grzelak A; Luczak M
    Med Dosw Mikrobiol; 2005; 57(4):409-16. PubMed ID: 16773834
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
    Melchers MJ; van Mil AC; Lagarde C; den Hartigh J; Mouton JW
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630197
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the MICs of cefepime for extended-spectrum beta-lactamase-producing and non-extended-spectrum beta-lactamase-producing strains of Enterobacter cloacae.
    Gottlieb T; Wolfson C
    J Antimicrob Chemother; 2000 Aug; 46(2):330-1. PubMed ID: 10933668
    [No Abstract]   [Full Text] [Related]  

  • 72. Cefepime in vitro activity against derepressed extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method.
    Naumiuk L; Samet A; Dziemaszkiewicz E
    J Antimicrob Chemother; 2001 Aug; 48(2):321-2. PubMed ID: 11481313
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical and microbiological observational study on AmpC β-lactamase-producing Enterobacteriaceae in a hospital of Nepal.
    Baral P; Neupane S; Shrestha B; Ghimire KR; Marasini BP; Lekhak B
    Braz J Infect Dis; 2013; 17(2):256-9. PubMed ID: 23453408
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing
    Shapiro S
    Antimicrob Agents Chemother; 2022 May; 66(5):e0029822. PubMed ID: 35471043
    [No Abstract]   [Full Text] [Related]  

  • 75. Comparison of sensitivity to a commercial
    Benameur Q; Gervasi T; Pellizzeri V; Pľuchtová M; Gruľová D; Cicero N; Meriem-Hind B
    Nat Prod Res; 2022 Jun; 36(11):2830-2835. PubMed ID: 34121535
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing.
    Rivera CG; Narayanan PP; Patel R; Estes LL
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3854-5. PubMed ID: 27067319
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations.
    Altshuler J; Guervil DJ; Ericsson CD; Wanger A; Aitken SL; Ostrosky-Zeichner L
    J Pharm Pract; 2018 Feb; 31(1):34-39. PubMed ID: 29278990
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence and Sensitivity of Bacilli and Pseudomonas in the Newborn's Oral Cavity.
    Ferreira PVA; Amêndola I; Oliveira LD; Silva CRGE; Leão MVP; Santos SSFD
    Braz Dent J; 2017; 28(4):423-427. PubMed ID: 29160392
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of the E test, a novel method of quantifying antimicrobial activity.
    Brown DF; Brown L
    J Antimicrob Chemother; 1991 Feb; 27(2):185-90. PubMed ID: 2055809
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?
    Pilmis B; Mizrahi A; Mory C; Le Monnier A; El Helali N
    Eur J Clin Microbiol Infect Dis; 2021 Jul; 40(7):1393-1397. PubMed ID: 33502648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.